Combined immuno-chemotherapy (R-CHOP) significantly improves time to treatment failure in first line therapy of follicular lymphoma -: Results of a prospective Randomized trial of the German Low Grade Lymphoma Study Group (GLSG).

被引：0
|
作者：
Hiddemann, W
Dreyling, MH
Forstpointner, R
Kneba, M
Woermann, B
Lengfelder, E
Schmits, R
Reiser, M
Metzner, B
Schmitz, N
Truemper, L
Eimermacher, H
Parwaresch, R
机构：
[1] Univ Munich, Hosp Grosshadern, Dept Internal Med 3, D-80539 Munich, Germany
[2] Univ Hosp Schleswig Holstein, Dept Internal Med 2, Kiel, Germany
[3] Hosp Braunschweig, Dept Internal Med, Braunschweig, Germany
[4] Univ Heidelberg, Hosp Mannheim, Dept Internal Med 3, D-6900 Heidelberg, Germany
[5] Univ Hosp Homburg Saar, Dept Internal Med 1, Homburg, Germany
[6] Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany
[7] Hosp Oldenburg, Dept Internal Med 2, Oldenburg, Germany
[8] Gen Hosp St Georg, Dept Internal Med, Hamburg, Germany
[9] Univ Hosp Goettingen, Dept Internal Med, Gottingen, Germany
[10] St Marien Hosp, Dept Med, Hagen, Germany
[11] Univ Hosp Schleswig Holstein, Dept Hematopathol, Kiel, Germany
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
352
引用
收藏
页码：104A / 104A
页数：1
相关论文
共 50 条
  • [31] Autologous Stem Cell Transplantation after Myeloablative Therapy in First Remission May Be Beneficial in Patients with Advanced Stage Follicular Lymphoma after Front-Line Therapy with R-CHOP. An Analysis of Two Consecutive Studies of the German Low Grade Lymphoma Study Group (GLSG)
    Hiddemann, Wolfgang
    Buske, Christian
    Kneba, Michael
    Dreyling, Martin
    Schmitz, Norbert
    Lengfelder, Eva
    Schmits, Rudolf
    Reiser, Marcel
    Metzner, Bernd
    Unterhalt, Michael
    BLOOD, 2008, 112 (11) : 286 - 287
  • [32] The Addition of Rituximab to CHOP Improves Failure-Free and Overall Survival of Mantle-Cell Lymphoma Patients - a Pooled Trials Analysis of the German Low-Grade Lymphoma Study Group (GLSG)
    Hoster, Eva
    Unterhalt, Michael
    Pfreundschuh, Michael
    Hallek, Michael
    Forstpointner, Roswitha
    Metzner, Bernd
    Einsele, Hermann
    Krauter, Juergen
    Duehrsen, Ulrich
    Ludwig, Wolf-Dieter
    Birkmann, Josef
    Peter, Norma
    Klapper, Wolfram
    Dreyling, Martin H.
    Hiddemann, Wolfgang
    BLOOD, 2014, 124 (21)
  • [33] Bendamustine/mitoxantrone/rituximab (BMR): A very effective and well tolerated immuno-chemotherapy for relapsed and refractory indolent lymphomas - Results of a Multicentre phase-II-study of the German low grade lymphoma study group (GLSG).
    Weide, R
    Koeppler, H
    Heymanns, J
    Thomalla, J
    Hess, G
    Gamm, H
    Aldaoud, A
    Schmitz, S
    Haak, U
    Plewe, D
    Burkhard, O
    Gaede, B
    Hinrichs, F
    Pflueger, KH
    Dreyling, M
    Unterhalt, M
    Hiddemann, W
    BLOOD, 2004, 104 (11) : 681A - 681A
  • [34] COMPARISON OF FIRST-LINE TREATMENT WITH BENDAMUSTINE PLUS RITUXIMAB VERSUS R-CHOP FOR PATIENTS WITH FOLLICULAR LYMPHOMA GRADE 3A: RESULTS OF AN ITALIAN MULTICENTER, RETROSPECTIVE STUDY
    Margiotta-Casaluci, G.
    Bigliardi, S.
    Cocito, F.
    Meli, E.
    Petrucci, L.
    Nicolosi, M.
    Annibali, O.
    Boccomini, C.
    Bozzola, V.
    Castellino, A.
    Cattina, F.
    Cenfra, N.
    Ciavarella, S.
    Kovalchuk, S.
    Rotondo, F.
    Fama, A.
    Olivieri, J.
    Zaja, F.
    HAEMATOLOGICA, 2021, 106 (10) : 91 - 91
  • [35] Rituximab Maintenance Versus Observation After Immunochemotherapy (R-CHOP, R-MCP, and R-FCM) in Untreated Follicular Lymphoma Patients: A Randomized Trial of the Ostdeutsche Studiengruppe Hamatologie und Onkologie and the German Low-Grade Lymphoma Study Group
    Hirt, Carsten
    Hoster, Eva
    Unterhalt, Michael
    Haenel, Mathias
    Prange-Krex, Gabriele
    Forstpointner, Roswitha
    Florschuetz, Axel
    Graeven, Ullrich
    Frickhofen, Norbert
    Wulf, Gerald
    Lengfelder, Eva
    Lerchenmueller, Christian
    Schlag, Rudolf
    Dierlamm, Judith
    Fischer von Weikersthal, Ludwig
    Ahmed, Asima
    Harich, Hanns-Detlev
    Rosenwald, Andreas
    Klapper, Wolfram
    Dreyling, Martin
    Hiddemann, Wolfgang
    Herold, Michael
    HEMASPHERE, 2021, 5 (07):
  • [36] Low initial trough concentration of rituximab is associated with unsatisfactory response of first-line R-CHOP treatment in patients with follicular lymphoma with grade 1/2
    Liu, Shu
    Huang, He
    Chen, Rong-xin
    Wang, Zhao
    Guan, Yan-ping
    Peng, Chen
    Fang, Xiao-jie
    Chen, Zhuo-jia
    Guan, Shao-xing
    Zhu, Xia
    Ren, Quan-guang
    Yao, Yu-yi
    Huang, Hong-bing
    Huang, Min
    Wang, Xue-ding
    Lin, Tong-yu
    ACTA PHARMACOLOGICA SINICA, 2021, 42 (04): : 641 - 647
  • [37] Allogeneic stem cell transplantation with dose-reduced conditioning in relapsed follicular and mantle cell lymphoma - A prospective phase II trial of the German low grade lymphoma study group (GLSG)
    Dreyling, Martin H.
    Beelen, D. -W.
    Schleuning, Michael
    Ho, Anthony D.
    Gramatzki, Martin
    Glas, B.
    Pfreundschuh, Michael
    Wilhelm, Martin
    Schmitz, Norbert
    Kolb, Hans-Jochem
    Unterhalt, Michael
    Hiddemann, Wolfgang
    BLOOD, 2007, 110 (11) : 899A - 899A
  • [38] Low initial trough concentration of rituximab is associated with unsatisfactory response of first-line R-CHOP treatment in patients with follicular lymphoma with grade 1/2
    Shu Liu
    He Huang
    Rong-xin Chen
    Zhao Wang
    Yan-ping Guan
    Chen Peng
    Xiao-jie Fang
    Zhuo-jia Chen
    Shao-xing Guan
    Xia Zhu
    Quan-guang Ren
    Yu-yi Yao
    Hong-bing Huang
    Min Huang
    Xue-ding Wang
    Tong-yu Lin
    Acta Pharmacologica Sinica, 2021, 42 : 641 - 647
  • [39] Prognostic determinants for long term outcome of low grade follicular lymphomas after cytoreductive chemotherapy and interferon alpha maintenance. Results of the German Low Grade Lymphoma Study Group (GLSG).
    Unterhalt, M
    Hermann, R
    Koch, P
    Trumper, L
    Bodenstein, H
    Dietzfelbinger, H
    Landys, K
    Reuss, M
    Vetter, H
    Maschmeyer, G
    Freund, M
    Neubauer, A
    Engert, A
    Stauder, R
    Herold, M
    Tiemann, M
    Parwaresch, R
    Stein, H
    Hiddemann, W
    BLOOD, 1997, 90 (10) : 1743 - 1743
  • [40] Bendamustine/mitoxantrone/rituximab (BMR):: A very effective and well tolerated immuno-chemotherapy for relapsed and refractory indolent lymphomas.: Results of a multicentre phase-II study of the German Low Grade Lymphoma Study Group (GLSG).
    Weide, R
    Heymanns, J
    Thomalla, J
    Köppler, H
    Hess, G
    Aldaoud, A
    Schmitz, S
    Unterhalt, M
    Dreyling, MH
    Hiddemann, W
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 589S - 589S
12345